Polyubiquitination inhibition of estrogen receptor alpha and its implications in breast cancer

INTRODUCTION

Estrogen receptor alpha (ERα) protein, also known as nuclear receptor subfamily3 group A member 1(NR3A1), comprises of 595 amino acids, organized in two activation function domains (AF-1 and AF-2), a DNA-binding domain (DBD), a ligand-binding domain (LBD)that recognize the 17beta-estradiol hormone (E2), and a hinge region that connects the DBD and the LBD[1-3](Figure 1). Many nuclear functions of ERα are triggered by the binding of E2 to the receptor[4,5], inducing ERα homodimers to bind to estrogen responsive elements(ERE) within the enhancer and promoter regions of E2-target genes[6,7]. In these events, pioneer factors expose chromatin sections, facilitating the association of ERα with EREs[8]. Moreover, transcriptional coregulators are recruited by the AF-1 and AF-2 domains of the receptor for the remodeling of the chromatin structure[9,10]and promotion of chromatin loops that modulate E2-responsive gene expression[11,12]. In addition, there is crosstalk between ERα and other signaling pathways:ERα acts as a coregulator by interacting with other transcription factors, such as activator protein 1 (AP-1),speci fi city protein 1 (Sp1), and nuclear factor-κB (NF-κB)[3,5,13-17]. Additionally, ERα is phosphorylated and transcriptionally activated in response to growth factors such as the epidermal growth factor (EGF) and insulinlike growth factor (IGF)[13,14,18-20]. Recently, progesterone receptor (PR) was shown as an ERα interacting protein that modulates and re–directs the binding of ERα to the chromatin and the expression of speci fi c genes in breast cancer cells [21] (Figure 2).

ERα also exhibits extranuclear activity by associating with the cell membrane via palmitoylation, and with the help of protein complexes, linked to the cell membrane or cytoplasm[22] (Figure 2). Thereafter, ERα transduces rapid extranuclear signaling that can trigger second messengers such as calcium and cAMP, and activate kinases such as ERK/MAPK, PI3K/AKT, PKC and Src kinase[13,23,24]. Both nuclear and extranuclear signaling of ERα are connected and are critical in about 70%of breast cancer cases (ERα+ breast cancer)[13,24,25].Consequently, ERα is a target for endocrine therapy via the use of selective estrogen receptor modulators(SERMs), such as tamoxifen (Tam), which competes with E2 by binding to ERα to inhibit its transcriptional activity,as well as, via the use of selective estrogen receptor degraders (SERDs) such as fulvestrant that decreases the ERα stability[8,14,26,27]. The acquisition of resistance to these treatments commonly occurs in ERα+ breast cancer, and although the mechanisms are unclear, the extranuclear signaling of ERα is strongly activated under this condition[19,20,26,28-31].

The activation or inhibition of ERα activity is modulated by its transcriptional coregulators, by phosphorylation induced by E2 hormones and growth factors, and by other posttranslational modifications such as ubiquitination.Remarkably, several studies have emerged to demonstrate that multiple mechanisms are activated in ERα+ breast cancers to inhibit ERα polyubiquitination, increasing its signaling pathways (Figure 2), which have crucial implications in the progression of this cancer type, as we will describe in the following sections.

GENERALITIES OF THE POSTTRANSLATIONAL MODIFICATION“UBIQUITINATION” FOR ERα IN BREAST CANCER CELLS

ERα is a monoubiquitination and polyubiquitination-target.However, fewer reports are available to demonstrate monoubiquitination of ERα, in comparison to those that exhibit polyubiquitination of this receptor. Nevertheless,these studies clearly show that ERα monoubiquitination is decreased by E2, and that, this modification is important, both for stability and for the transcriptional activity of this receptor in breast cancer. In contrast,polyubiquitination is induced by E2, resulting in a signal to direct ERα degradation via the UPS[14,32,33], facilitated by the concerted action of the enzymes E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme),and E3 (ubiquitin ligase)[32,33]. The specific covalent binding of ubiquitin to ERα lysine residues is mediated by several E3 ubiquitin ligases for ERα, that include CHIP[34],E6AP[35], BRCA1[36], BARD1[37], SKP2[38], MDM2[39],and Hbo1[40]. Importantly, E2 treatment induces ERα polyubiquitination, followed by its degradation by the UPS[14,17,33,41-43].

Although polyubiquitination leads to ERα downregulation through its degradation by the 26S proteasome,it is important to note that, this modification and the proteasome activity, have also been reported as elements required for the transcriptional cycle of ERα.Likewise, it has been evidenced that ERα bound to ERE can recruit coactivators, some of which possess E3-ubiquitin ligase activity, such as SKP2[17], E6AP, and RNF8. As coactivators enhance the activity of ERα,and the activity of E3-ubiquitin ligases mediate the downregulation of this receptor, the recruitment of these proteins with dual function may maintain a balance in the level and activity of ERα[17,44,45].

ERα residues, K302 and K303, have been suggested as the lysine targets for ubiquitination and degradation,in response to E2 and fulvestrant, but the same residues are also important for ERα stability in untreated breast cancer cells[46]. Against this background, it maybe envisaged that, several factors delicately modulate the stability and degradation of ERα, which may be altered in breast cancer.

生活化的教学理念是一种先进的教学理念，生活化的课堂教学是一种先进的教学方式，在教学中有着明显的优势，其首先体现在其突出学生的主体地位和挖掘学生的学习潜力上。

Additionally, the ubiquitination of ERα is also related to its phosphorylation state. Several kinases, such as CDK11p58[47], cyclin E-CDK2[17], Src[35], PKC[42],p38MAPK[38], and ERK7[48] have been reported as modi fi ers of ERα in breast cancer. The main residues of ERα that are phosphorylated in E2-response, and have been associated with its polyubiquitination and degradation, are S118[49],S294[38], S341[17], and Y537[35]. A key example is the sequential modi fi cation of ERα, where, fi rst, the ERα Y537 residue is phosphorylated by Src kinase in E2-treated cells, followed by E6AP, an E3-ubiquitin ligase, which induces ERα polyubiquitination and its degradation[35].Thus, phosphorylation and ubiquitination of ERα are interconnected in order to control both, the abundance and the functions of this receptor.

IS ERα IN BREAST CANCER CELLS POLYUBIQUITINATED AND DEGRADED?

In recent years, several studies have emerged to demonstrate the inhibition of polyubiquitination of ERα and consequently, a decrease in its degradation via the UPS, increasing its protein stability in breast cancer cells, through several mechanisms and ERα-associated proteins. Here, we describe these evidences.

ERα polyubiquitination inhibitor proteins in breast cancer cells

Among EPIIs, PEBP4 inhibits ERα polyubiquitination and enhances its transcriptional activity in breast cancer cells. Because PEBP4 is overexpressed in breast cancer and competes with ERα for components of the UPS, this protein may be an important target for breast cancer. Additionally, specific posttranslational modifications, such as palmitoylation, acetylation and phosphorylation, as well as, mutations of sites linked to ERα polyubiquitination and degradation, demands more research to fi nd new strategies for detection and treatment of breast cancer.

2008年国务院发布《国家知识产权局战略纲要》，明确了到2020年把我国建设成为知识产权创造、运用、保护和管理水平较高的国家战略目标。一些机构如商标代理类机构在政策的催化下快速发展，但与其他国家相比，我国知识产权工作起步较晚。随着我国对知识产权工作的重视，企业开始积极配合国家政策，大量引进创新型人才，取得了一定效果。随着知识产权案件数量的累积，我国企业开始不断加大培养创新型人才团队的各种投入，但在追赶其他国家知识产权优势的过程中，农业领域的知识产权转换效率仍偏低。

（1）中国大部分城市大气降尘中重金属元素As、Hg、Cd、Cr、Cu、Ni、Pb 和 Zn 的平均值均高于中国土壤背景值，存在一定程度的污染。Cd在工业区和非工业区中的污染级别最高，污染程度最强。非工业区中的Cd是土壤背景值33倍，主要来自燃煤和车辆尾气；工业区中的Cd超标高达200多倍，主要来自冶炼企业的排放。Cr和Ni的含量在非工业区和工业区中差别不大。

ERα polyubiquitination for its downregulation via the UPS,is a central mechanism of some endocrine therapies with SERDs, such as fulvestrant[46,75]. Clearly, the induction of ERα polyubiquitination for its degradation decreases the abundance and pro-tumor activity of ERα, consequently novel drugs including AZD9496[76], GDC-0810[77], bazedoxifene[78], and RAD1901[79] have been synthetized as SERDs, but more studies are required. Despite the importance of SERDs in the therapy of breast cancer,EPIP are promising targets for the management of this disease. Remarkably, the proteins that inhibit the ERα polyubiquitination are enhanced in ERα+ breast cancers,contributing to disease progression. For this reason,EPIP may be useful as a biomarker for breast cancer and as a therapeutic target.

Interestingly, E3 ubiquitin ligases such as RNF8,RNF31, SHARPIN, and SMURF1 interact with ERα to block its polyubiquitination and to promote the proliferation of breast cancer cells. RNF8, RNF31, and SHARPIN inhibit ERα polyubiquitination by catalyzing monoubiquitination of this receptor, and as a result, ERα protein levels and E2-dependent transcriptional activity are enhanced in breast cancer cells[65]. SHARPIN could monoubiquitinate the ERα K302/303, but whether these residues are also modified by RNF8 and/or RNF31 is unclear. Moreover,RNF8 also acts as a coactivator for ERα in breast cancer cells. Instead, SMURF1 apparently inhibits polyubiquitination of ERα, but the implicated mechanisms need to be studied[65-68].

On the other hand, RB induces the assembly of ERα with chaperone proteins[64]. Hence, retinoblastoma (RB)interacts with ERα, HSP90, and p23 in the cytoplasm to protect ERα from polyubiquitination and degradation by the UPS. ERα is highly ubiquitinated and degraded in RB-knockdown cells; however, its levels are restored with MG132 (a proteasome inhibitor) treatment in breast cancer[64].

(1)含矿岩类(铅锌矿化、黄铁矿化、铜矿化)的视极化率较高(一般大于4%)，具有中高极化率特征，极化率的高低取决于矿石含铅锌矿和黄铁矿等金属硫化物的多少；且视极化率变化范围大，受岩矿石内部金属物质含量及排列情况影响大；氧化矿的视极化率一般较低，主要是因为其铁质成分被氧化为褐铁矿，硫质成分减少。

Other examples are GSK3, LMTK3, and ABL1 kinases that phosphorylate ERα to inhibit its polyubiquitination[58,59].First, the glycogen synthase kinase-3 (GSK3) isoforms interact with and phosphorylate ERα at S102, S104,S106, and S118. GSK3 depletion decreases phosphorylation and E2-induced transcriptional activity by increasing polyubiquitination and degradation of this receptor[59-61]. Thereafter, LMTK3 (lemur tyrosine kinase 3)interacts with and phosphorylates ERα to protect it from polyubiquitination and degradation via the UPS in breast cancer cells[58]. Similarly, ABL (ABL proto-oncogene 1, non-receptor tyrosine kinase) interacts with and phosphorylates ERα at Y52 and Y219, increasing the ERα stability and resistance to Tam; both proteins are increased in breast tumor tissue samples[62,63].

Other proteins and modifications that inhibit ERα polyubiquitination

ERα polyubiquitination indirect inhibitors (EPII), intriguingly,the inhibition of ERα polyubiquitination also occurs with the help of other proteins that lack the ability to directly interact with ERα. For instance, it has been suggested that Src-dependent phosphorylation of ERα allows E6AP to polyubiquitinate and induce the degradation of this receptor. However, PEBP4 (phosphatidyl ethanolaminebinding protein 4) protein[69,70] interacts with Src, blocking the phosphorylation and degradation of ERα induced by Src[69].

Furthermore, although the mechanisms are unclear,it has been reported that ERα protein levels decrease in cells with low levels of REGγ (PA28γ, a nuclear proteasome coactivator), but when the proteasome is inhibited by MG132 treatment, ERα protein levels are recovered,suggesting that downregulation of REGγ promotes ERα polyubiquitination and degradation. High levels of REGγ and ERα in breast tumors correlated with poor prognosis in patients with breast cancer[69].

Additionally, some posttranslational modifications are also associated with ERα polyubiquitination inhibition.Hence, ERα acetylation induced by trichostatin (a deacetylase inhibitor) increases the p300 levels and the stability of the receptor in breast cancer cells, but the mechanisms implicated need to be investigated(Figure 1)[71]. Palmitoylation has also been linked to ERα polyubiquitination since it has been shown that the ERα mutants that cannot be palmitoylated are polyubiquitinated and degraded via UPS[72].

Mutations and modifications that affect ERα polyubiquitination detected in mammary tumors from patients

ERα polyubiquitination has a clinical relevance, since mutations and/or posttranslational modifications such as phosphorylation in residues of ERα have been identi fi ed in tumor tissues from samples of patients with breast cancer, and these residues have been linked to the polyubiquitination and downregulation by degradation of this receptor. Thus, the Y537 residue is required for the ERα phosphorylation, and this modi fi cation subsequently promotes polyubiquitination and degradation of the receptor[35]. However, mutations in the residues Y537N,Y537C, and Y537S are detected in mammary tumors of patients with metastasis and endocrine resistance.Accordingly, ERα polyubiquitination and degradation is prevented by experimentally induced mutations at the Y537 residue, and similarly, these mutations have been associated with the development of endocrine therapy resistance in breast cancer[15,73,74]. In the same way, the K303 residue is needed for ERα polyubiquitination and degradation, but this residue has been identi fi ed to be mutated as K303R in tumors of patients who have poor survival outcome and prognosis[46,74]. Other residues, such as S104, S106, S118, and S294, that seem to be related with ERα stability, have been found to be phosphorylated in breast tumor samples[15,73].

ERα POLYUBIQUITINATION INHIBITION IN BREAST CANCER AS A KEY FACTOR FOR THERAPEUTIC STRATEGY

MUC1 and Protein interacting with Never in mitosis A (PIN1), for example, induce the formation of stable transcription complexes on the DNA[49,50]. MUC1 interacts with ERα to inhibit its polyubiquitination and degradation,and recruits coactivators such as SRC1 and GRIP on E2-regulated promoters to enhance gene transcription linked to cellular proliferation, migration, tumorigenicity,and endocrine resistance[50-54]. Likewise, PIN1 interacts with ERα phosphorylated at S118, inducing its cis/trans isomerization. Moreover, PIN1 blocks the polyubiquitination and degradation of ERα by preventing its interaction with the E6AP E3 ligase, hence enhancing its stability,binding to EREs, and the subsequent transcriptional activity of ERα[10,49,55-57]. High levels of PIN1 and ERα, and low levels of E6AP are observed in endocrine resistance[49].

PIN1 is overexpressed in breast cancer and is related to mammary tumor growth, and epithelial-mesenchymal transition, and natural and synthetic inhibitors are being probed to control its activity[55,57,80-87]. Similarly, LMTK3 overexpression stimulates cellular proliferation and tumor formation, and correlates with shorter survival times in ERα+ breast cancer, and resistance to Tam treatment,but these events are reduced when LMTK3 expression is decreased[58,88-90]. Moreover, CG0009, is a GSK3 inhibitor that decreases proliferation of breast cancer cells[61,73,91-94].

为落实安全生产“百日攻坚”行动，健全安全生产风险防控和隐患排查治理双重预防机制。11月27日，四师六十一团党委领导带领团经发办、城镇管理中心、农业发展中心、社会事务办公室等相关工作人员，对该团社区、水管所、幼儿园、养老院、酒店、农药店、民营企业、水库等重点防范部位和10个连队进行了为期四天的安全生产大检查。

Interestingly, MUC1-C subunit interacts with DBD of ERα promoting (1) Inhibition of ERα polyubiquitination maintaining high levels of this receptor; (2) a stable complex between MUC1-C and ERα; and (3) an enhancement in the pro-tumor transcriptional activity of ERα since SRC1 and GRIP coactivators with histone acetyltransferase activity are recruited by MUC1[50]. Thus,MUC1-C increases the growth and survival induced by E2 in breast cancer cells, but also transformation, loss of cellular polarity, cellular proliferation and migration,anchorage-independent growth , and tumorigenicity in transgenic mouse models[51,99,102-104].

ERα polyubiquitination inhibitor proteins (EPIP). There has been a progressive increase in the number of ERα polyubiquitination inhibitor proteins that have been discovered in breast cancer cells, which we have grouped and identi fi ed as EPIP. So far, it has been reported that proteins such as Mucin 1 (MUC1), PIN1, GSK3, LMTK3,RNF8, RNF31, RB, ABL, SHARPIN, and SMURF1 have the ability to interact with ERα, conferring it protection against polyubiquitination and degradation. Interestingly,not all of these proteins have related sequences and structures, but some of them are functionally similar.

《占名穴地师报德》讲述了一地师因受村舍主翁“一饭之德”，便请为主翁占地，主翁说：“吾家计稍饶，无他所求，而年过五十，尚无一子，若占得得嗣之地，毋至绝祀之境，则幸也。”他希望地师通过占地让他得嗣。 地师领其至村后一处，占穴曰：“此是连生三子之地，君其用之。”并相约“十年当复来”，预言“其间必生三男”[7]345。 果然，主翁之妻死过三年后，主翁续娶一少妇，后来连生三子。

Muc1 is an EPIP in breast cancer

Mucin 1 (MUC1) is a heterodimeric glycoprotein conformed by MUC1 N-terminal (MUC1-N) and MUC1 C-terminal(MUC1-C) subunits[52]. MUC1-N is an extracellular glycosylated subunit and MUC1-C is a transmembrane subunit with a cytoplasmic domain that interacts with diverse proteins[54]. MUC1 is localized on the apical borders in normal mammary epithelium, but under breast cancer conditions, it also localizes to the nucleus. An aberrant expression of MUC1-C is detected in breast cancer cells through a regulation loop that implicates Rab31 protein inhibits the lysosomal degradation of MUC1-C, and Rab31 gene expression is induced by MUC1-C[52-54,99].Furthermore, MUC1 is upregulated in 90% of breast cancers, where the expression of Rab31 gene and other genes associated with endocrine resistance are modu-lated by the MUC1-C/ERα complex. For these reasons,MUC1 has been suggested as a potential biomarker of breast cancer and predictor of resistance to Tam treatment[51,100,101] (Figure 3).

Another molecule is RNF31, whose overexpression increases ERα protein levels, expression of ERα target genes and the growth of breast cancer cells, and these events are decreased when RNF31 is abated[65]. Lastly,the loss of RB expression seems to be related to the loss of ERα stability in ERα negative (ERα–) breast cancers and with poor responses to hormonal therapies in patients[64,95-98]. Thus, these proteins can be potential biomarkers and target for the treatment of ERα+ breast cancer.

Remarkably, MUC1 is an EPIP involved in proliferation and endocrine resistance[50,53,54,100,105], inhibited by miR-125b[106], miR-145[104], miR-1226[103], and by speci fi c siRNAs, inducing apoptosis, reducing cell proliferation, and increasing sensitivity to Tam[100]. Similarly, apigenin[107],and the synthetic peptides GO-201[54] and GO-203[100],affect localization and dimerization of MUC1, and as a result, tumor development is decreased, and sensitivity to Tam is increased[54,100,107]. Moreover, MUC1-based rBCG (Bacillus Calmette-Guerin) vaccines induce anti-MUC immune responses inhibiting the growth of tumors in mice[108,109]. Interestingly, high levels of Rab31 antigen have been associated with a proliferative status, a high tumor grade, and with poor 5-year disease-free survival in patients with ERα+ breast cancer. Consequently, the Rab31 antigen levels in mammary tumors have been suggested as a biomarker for ERα+ breast cancers that may also to be useful in the selection of patients for MUC1-targeted therapeutic strategies[110].

CONCLUSION

Several mechanisms seem to cooperate to inhibit ERα polyubiquitination, decreasing its degradation in ERα+breast cancer cells. These cells become resistant to ERα polyubiquitination due to the evident upregulation of proteins, modifications, and mutations that protect it from ubiquitination. There is no pattern of the characteristics of the inhibitor or protector proteins for ERα polyubiquitination. Some of the reported EPIPs are MUC1, GSK3, LMTK3, RNF8, RNF31, SHARPIN, SMURF1,RB, and PIN1. All of them inhibit ERα polyubiquitination and its degradation in a dissimilar manner, via subcellular compartments or mechanisms. Some of them can be grouped as coactivators for ERα (MUC1, PIN1, and RNF8), kinases for ERα (GSK3, LMTK3, and ABL1), E3 ubiquitin ligase (RNF8, RNF31, SHARPIN, and SMURF1),and scaffold protein (RB). Amongst these different mechanisms, the participation of E3-ubiquitin ligases,such as RNF8, RNF31, and SHARPIN, are interesting,since they catalyze ERα monoubiquitination, suggesting a possible competition between monoubiquitination and polyubiquitination of this receptor.

甲洛洛看着很多人挤在柜台前，等待着西西称盐和白糖，西西忙得不可开交，小丁在边上帮着忙活。有几次西西艰难地搬动着两百斤的盐袋，他想上前帮帮忙，可这念头还没理清是否可行，嘎绒就出现了，出现得那么及时，好像他的工作就是西西需要帮助时搭上一手。

Considering the fi ndings described above, inhibition of ERα polyubiquitination, increases its abundance,and the expression of E2-dependent genes linked to proliferation and tumor development. In addition,inhibition of ERα polyubiquitination may have other serious implications, since it has been reported that this modi fi cation and proteasome activity are coupled to the transcriptional cycle of this receptor[45]. Moreover, it has been proposed that high ERα protein levels are related to ERα binding to other DNA regulatory regions of genes that are atypically activated under this condition[111].Thus, inhibition of ERα polyubiquitination and its degradation increases the stability of this receptor, but also affects ERα/E2 signaling and its transcriptional activity,involved with the development of tumor and endocrine resistance[111,112] (Figure 4).

1.父母和孩子交流时应该平心静气，不要因为孩子与自己的想法不一样而发火，要给孩子申辩的机会，让他们说出自己的真实感受。如果双方分歧确实很大，父母不妨放弃争论，再找合适的机会和孩子沟通。

Importantly, there is an interplay between inhibition of ERα polyubiquitination and endocrine therapy resistance in ERα+ breast cancer, promoted by EPIP and EPII [49,50,58,65]. In contrast, in luminal B breast cancers or ERα– breast cancers, RB is commonly lost or dysfunctional, leading to high levels of polyubiquitination and degradation of ERα, with a poor prognosis for patients. Therefore, EPIP, EPII, and mutations and modifications that inhibit ERα polyubiquitination and degradation may act in a cooperative manner to enhance the stability of the receptor in the progression of breast cancer. Consequently, the mechanisms involved in the inhibition of ERα polyubiquitination represent useful biomarkers, therapeutic targets, and prognostic indicators of endocrine therapy in breast cancer.

In conclusion, EPIP, EPII, and mutations and modi fications associated to ERα polyubiquitination inhibition,enhance the signaling pathways of this receptor. These fi ndings represent a new fi eld in breast cancer, for the establishment of potential biomarkers, as well as, in the design of effective therapeutic targets to control the progression of this disease. Integration between the molecular basis of ERα inhibition and its correlation with the progression of breast tumors remains to be elicited.

ACKNOWLEDGMENTS

We thank Dr. Bibiana Ortega Dominguez for her helpful review of the manuscript.

REFERENCES

1 Germain P, Staels B, Dacquet C, Spedding M, Laudet V. Overview of nomenclature of nuclear receptors. Pharmacol Rev 2006; 58:685 704 [PMID: 17132848 DOI: 10.1124/pr.58.4.2]

2 Kumar R, Zakharov MN, Khan SH, Miki R, Jang H, Toraldo G,Singh R, Bhasin S, Jasuja R. The dynamic structure of the estrogen receptor. J Amino Acids 2011; 2011: 812540 [PMID: 22312471 DOI: 10.4061/2011/812540]

3 Ng HW, Perkins R, Tong W, Hong H. Versatility or promiscuity:the estrogen receptors, control of ligand selectivity and an update on subtype selective ligands. Int J Environ Res Public Health 2014;11: 8709 8742 [PMID: 25162709 DOI: 10.3390/ijerph110908709]

4 Manavathi B, Dey O, Gajulapalli VN, Bhatia RS, Bugide S,Kumar R. Derailed estrogen signaling and breast cancer: an au thentic couple. Endocr Rev 2013; 34: 1 32 [PMID: 22947396 DOI:10.1210/er.2011 1057]

5 Vrtačnik P, Ostanek B, Mencej-Bedrač S, Marc J. The many faces of estrogen signaling. Biochem Med (Zagreb) 2014; 24: 329 342[PMID: 25351351 DOI: 10.11613/BM.2014.035]

6 Hah N, Kraus WL. Hormone regulated transcriptomes: lessons learned from estrogen signaling pathways in breast cancer cells.Mol Cell Endocrinol 2014; 382: 652 664 [PMID: 23810978 DOI:10.1016/j.mce.2013.06.021]

7 Hah N, Murakami S, Nagari A, Danko CG, Kraus WL. Enhancer transcripts mark active estrogen receptor binding sites. Genome Res 2013; 23: 1210 1223 [PMID: 23636943 DOI: 10.1101/gr.152306.112]

8 Manavathi B, Samanthapudi VS, Gajulapalli VN. Estrogen re ceptor coregulators and pioneer factors: the orchestrators of mam mary gland cell fate and development. Front Cell Dev Biol 2014; 2:34 [PMID: 25364741 DOI: 10.3389/fcell.2014.00034]

9 Hervouet E, Cartron PF, Jouvenot M, Delage Mourroux R.Epigenetic regulation of estrogen signaling in breast cancer.Epigenetics 2013; 8: 237 245 [PMID: 23364277 DOI: 10.4161/epi.23790]

10 Rajbhandari P, Finn G, Solodin NM, Singarapu KK, Sahu SC,Markley JL, Kadunc KJ, Ellison Zelski SJ, Kariagina A, Haslam SZ, Lu KP, Alarid ET. Regulation of estrogen receptor α N terminus conformation and function by peptidyl prolyl isomerase Pin1. Mol Cell Biol 2012; 32: 445 457 [PMID: 22064478 DOI: 10.1128/MCB.06073 11]

11 He C, Wang X, Zhang MQ. Nucleosome eviction and multiple co factor binding predict estrogen receptor alpha associated long range interactions. Nucleic Acids Res 2014; 42: 6935 6944 [PMID:24782518 DOI: 10.1093/nar/gku327]

12 Liu MH, Cheung E. Estrogen receptor mediated long range chromatin interactions and transcription in breast cancer. Mol Cell Endocrinol 2014; 382: 624 632 [PMID: 24071518 DOI: 10.1016/j.mce.2013.09.019]

13 Acconcia F, Kumar R. Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett 2006;238: 1 14 [PMID: 16084012 DOI: 10.1016/j.canlet.2005.06.018]

14 Kerdivel G, Flouriot G, Pakdel F. Modulation of estrogen receptor alpha activity and expression during breast cancer progression.Vitam Horm 2013; 93: 135 160 [PMID: 23810005 DOI: 10.1016/B978 0 12 416673 8.00004 6]

15 Le Romancer M, Poulard C, Cohen P, Sentis S, Renoir JM, Corbo L. Cracking the estrogen receptor’s posttranslational code in breast tumors. Endocr Rev 2011; 32: 597 622 [PMID: 21680538 DOI:10.1210/er.2010 0016]

16 Soltysik K, Czekaj P. Membrane estrogen receptors is it an alte rnative way of estrogen action? J Physiol Pharmacol 2013; 64:129 142 [PMID: 23756388]

17 Zhou W, Srinivasan S, Nawaz Z, Slingerland JM. ERα, SKP2 and E2F 1 form a feed forward loop driving late ERα targets and G1 cell cycle progression. Oncogene 2014; 33: 2341 2353 [PMID:23770852 DOI: 10.1038/onc.2013.197]

18 Treviño LS, Weigel NL. Phosphorylation: a fundamental regula tor of steroid receptor action. Trends Endocrinol Metab 2013; 24:515 524 [PMID: 23838532 DOI: 10.1016/j.tem.2013.05.008]

19 Tecalco-Cruz AC, Pérez Alvarado IA, Ramírez Jarquín JO,Rocha Zavaleta L. Nucleo cytoplasmic transport of estrogen receptor alpha in breast cancer cells. Cell Signal 2017; 34: 121 132[PMID: 28341599 DOI: 10.1016/j.cellsig.2017.03.011]

20 Tecalco-Cruz AC, Ramírez Jarquín JO. Mechanisms that Increase Stability of Estrogen Receptor Alpha in Breast Cancer. Clin Breast Cancer 2017; 17: 1 10 [PMID: 27561704 DOI: 10.1016/j.clbc.2016.07.015]

21 Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE,Tarulli GA, Serandour AA, Birrell SN, Bruna A, Saadi A, Menon S, Had fi eld J, Pugh M, Raj GV, Brown GD, D’Santos C, Robinson JL, Silva G, Launchbury R, Perou CM, Stingl J, Caldas C, Tilley WD, Carroll JS. Corrigendum: Progesterone receptor modulates ERα action in breast cancer. Nature 2015; 526: 144 [PMID:26245370 DOI: 10.1038/nature14959]

22 Pedram A, Razandi M, Deschenes RJ, Levin ER. DHHC 7 and 21 are palmitoylacyltransferases for sex steroid receptors. Mol Biol Cell 2012; 23: 188 199 [PMID: 22031296 DOI: 10.1091/mbc.E11 07 0638]

23 Acconcia F, Marino M. The Effects of 17β-estradiol in Cancer are Mediated by Estrogen Receptor Signaling at the Plasma Membrane. Front Physiol 2011; 2: 30 [PMID: 21747767 DOI:10.3389/fphys.2011.00030]

24 Marino M, Galluzzo P, Ascenzi P. Estrogen signaling multiple pathways to impact gene transcription. Curr Genomics 2006; 7:497 508 [PMID: 18369406 DOI: 10.2174/138920206779315737]

25 Miyoshi Y, Murase K, Saito M, Imamura M, Oh K. Mechanisms of estrogen receptor α upregulation in breast cancers. Med Mol Morphol 2010; 43: 193 196 [PMID: 21267694 DOI: 10.1007/s00795 010 0514 3]

26 Cook KL, Shajahan AN, Clarke R. Autophagy and endocrine re sistance in breast cancer. Expert Rev Anticancer Ther 2011; 11:1283 1294 [PMID: 21916582 DOI: 10.1586/era.11.111]

27 Magnani L, Brunelle M, Gévry N, Lupien M. Chromatin landscape and endocrine response in breast cancer. Epigenomics 2012; 4:675 683 [PMID: 23244312 DOI: 10.2217/epi.12.64]

28 de Leeuw R, Neefjes J, Michalides R. A role for estrogen receptor phosphorylation in the resistance to tamoxifen. Int J Breast Cancer 2011; 2011: 232435 [PMID: 22295213 DOI: 10.4061/2011/232435]

29 Johnson AB, O’Malley BW. ERasing breast cancer resistance through the kinome. Nat Med 2011; 17: 660 661 [PMID: 21647142 DOI: 10.1038/nm0611 660]

30 Muluhngwi P, Klinge CM. Roles for miRNAs in endocrine resistance in breast cancer. Endocr Relat Cancer 2015; 22: R279 R300 [PMID:26346768 DOI: 10.1530/ERC 15 0355]

31 Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011; 62: 233 247 [PMID: 20887199 DOI: 10.1146/annurev med 070909 182917]

32 Helzer KT, Hooper C, Miyamoto S, Alarid ET. Ubiquitylation of nuclear receptors: new linkages and therapeutic implications.J Mol Endocrinol 2015; 54: R151 R167 [PMID: 25943391 DOI:10.1530/JME 14 0308]

33 Zhou W, Slingerland JM. Links between oestrogen receptor activation and proteolysis: relevance to hormone regulated cancer therapy. Nat Rev Cancer 2014; 14: 26 38 [PMID: 24505618 DOI:10.1038/nrc3622]

34 Fan M, Park A, Nephew KP. CHIP (carboxyl terminus of Hsc70 interacting protein) promotes basal and geldanamycin induced degradation of estrogen receptor alpha. Mol Endocrinol 2005; 19:2901 2914 [PMID: 16037132 DOI: 10.1210/me.2005 0111]

35 Sun J, Zhou W, Kaliappan K, Nawaz Z, Slingerland JM. ERα phosphorylation at Y537 by Src triggers E6 AP ERα binding, ERα ubiquitylation, promoter occupancy, and target gene expression.Mol Endocrinol 2012; 26: 1567 1577 [PMID: 22865929 DOI:10.1210/me.2012 1140]

36 Eakin CM, Maccoss MJ, Finney GL, Klevit RE. Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase. Proc Natl Acad Sci USA 2007; 104: 5794 5799 [PMID: 17392432 DOI:10.1073/pnas.0610887104]

37 Hashizume R, Fukuda M, Maeda I, Nishikawa H, Oyake D, Yabuki Y, Ogata H, Ohta T. The RING heterodimer BRCA1 BARD1 is a ubiquitin ligase inactivated by a breast cancer derived mutation.J Biol Chem 2001; 276: 14537 14540 [PMID: 11278247 DOI:10.1074/jbc.C000881200]

38 Bhatt S, Xiao Z, Meng Z, Katzenellenbogen BS. Phosphorylation by p38 mitogen activated protein kinase promotes estrogen receptor α turnover and functional activity via the SCF(Skp2)proteasomal complex. Mol Cell Biol 2012; 32: 1928 1943 [PMID:22431515 DOI: 10.1128/MCB.06561 11]

39 Saji S, Okumura N, Eguchi H, Nakashima S, Suzuki A, Toi M,Nozawa Y, Saji S, Hayashi S. MDM2 enhances the function of estrogen receptor alpha in human breast cancer cells. Biochem Biophys Res Commun 2001; 281: 259 265 [PMID: 11178989 DOI:10.1006/bbrc.2001.4339]

40 Iizuka M, Susa T, Tamamori Adachi M, Okinaga H, Okazaki T.Intrinsic ubiquitin E3 ligase activity of histone acetyltransferase Hbo1 for estrogen receptor α. Proc Jpn Acad Ser B Phys Biol Sci 2017; 93: 498 510 [PMID: 28769019 DOI: 10.2183/pjab.93.030]

41 Kocanova S, Mazaheri M, Caze Subra S, Bystricky K. Ligands specify estrogen receptor alpha nuclear localization and degradation. BMC Cell Biol 2010; 11: 98 [PMID: 21143970 DOI:10.1186/1471 2121 11 98]

42 Marsaud V, Gougelet A, Maillard S, Renoir JM. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha),differentially affect ERalpha extractability, proteasome mediated stability, and transcriptional activity in human breast cancer cells.Mol Endocrinol 2003; 17: 2013 2027 [PMID: 12855746 DOI:10.1210/me.2002 0269]

43 Valley CC, Solodin NM, Powers GL, Ellison SJ, Alarid ET. Temporal variation in estrogen receptor alpha protein turnover in the presence of estrogen. J Mol Endocrinol 2008; 40: 23 34 [PMID: 18096994 DOI: 10.1677/JME 07 0067]

44 Lonard DM, Nawaz Z, Smith CL, O’Malley BW. The 26S proteasome is required for estrogen receptor alpha and coactivator turnover and for ef fi cient estrogen receptor-alpha transactivation.Mol Cell 2000; 5: 939 948 [PMID: 10911988 DOI: 10.1016/S1097 2765(00)80259 2]

45 Reid G, Hübner MR, Métivier R, Brand H, Denger S, Manu D,Beaudouin J, Ellenberg J, Gannon F. Cyclic, proteasome mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 2003; 11: 695 707 [PMID: 12667452 DOI: 10.1016/S1097 2765(03)00090 X]

46 Berry NB, Fan M, Nephew KP. Estrogen receptor alpha hinge region lysines 302 and 303 regulate receptor degradation by the proteasome. Mol Endocrinol 2008; 22: 1535 1551 [PMID:18388150 DOI: 10.1210/me.2007 0449]

47 Wang Y, Zong H, Chi Y, Hong Y, Yang Y, Zou W, Yun X, Gu J.Repression of estrogen receptor alpha by CDK11p58 through promoting its ubiquitin proteasome degradation. J Biochem 2009;145: 331 343 [PMID: 19122208 DOI: 10.1093/jb/mvn177]

48 Henrich LM, Smith JA, Kitt D, Errington TM, Nguyen B, Traish AM, Lannigan DA. Extracellular signal regulated kinase 7, a regulator of hormone dependent estrogen receptor destruction. Mol Cell Biol 2003; 23: 5979 5988 [PMID: 12917323 DOI: 10.1128/MCB.23.17.5979 5988.2003]

49 Rajbhandari P, Schalper KA, Solodin NM, Ellison Zelski SJ,Ping Lu K, Rimm DL, Alarid ET. Pin1 modulates ERα levels in breast cancer through inhibition of phosphorylation dependent ubiquitination and degradation. Oncogene 2014; 33: 1438 1447[PMID: 23542176 DOI: 10.1038/onc.2013.78]

50 Wei X, Xu H, Kufe D. MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell 2006; 21: 295 305 [PMID:16427018 DOI: 10.1016/j.molcel.2005.11.030]

51 Ghosh SK, Uchida M, Yoo B, Ross AW, Gendler SJ, Gong J, Moore A, Medarova Z. Targeted imaging of breast tumor progression and therapeutic response in a human uMUC 1 expressing transgenic mouse model. Int J Cancer 2013; 132: 1860 1867 [PMID:23015160 DOI: 10.1002/ijc.27872]

52 Haddon L, Hugh J. MUC1 mediated motility in breast cancer: a review highlighting the role of the MUC1/ICAM 1/Src signaling triad. Clin Exp Metastasis 2015; 32: 393 403 [PMID: 25759211 DOI: 10.1007/s10585 015 9711 8]

53 Jin C, Rajabi H, Pitroda S, Li A, Kharbanda A, Weichselbaum R,Kufe D. Cooperative interaction between the MUC1 C oncoprotein and the Rab31 GTPase in estrogen receptor positive breast cancer cells. PLoS One 2012; 7: e39432 [PMID: 22792175 DOI: 10.1371/journal.pone.0039432]

54 Raina D, Ahmad R, Joshi MD, Yin L, Wu Z, Kawano T, Vasir B,Avigan D, Kharbanda S, Kufe D. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res 2009; 69: 5133 5141 [PMID:19491255 DOI: 10.1158/0008 5472.CAN 09 0854]

55 Lu Z, Hunter T. Prolyl isomerase Pin1 in cancer. Cell Res 2014;24: 1033 1049 [PMID: 25124924 DOI: 10.1038/cr.2014.109]

56 Rajbhandari P, Ozers MS, Solodin NM, Warren CL, Alarid ET.Peptidylprolyl Isomerase Pin1 Directly Enhances the DNA Binding Functions of Estrogen Receptor α. J Biol Chem 2015; 290:13749 13762 [PMID: 25866209 DOI: 10.1074/jbc.M114.621698]

57 Wang JZ, Liu BG, Zhang Y. Pin1 based diagnostic and therapeutic strategies for breast cancer. Pharmacol Res 2015; 93: 28 35 [PMID:25553719 DOI: 10.1016/j.phrs.2014.12.005]

58 Giamas G, Filipović A, Jacob J, Messier W, Zhang H, Yang D,Zhang W, Shifa BA, Photiou A, Tralau Stewart C, Castellano L,Green AR, Coombes RC, Ellis IO, Ali S, Lenz HJ, Stebbing J.Kinome screening for regulators of the estrogen receptor identi fi es LMTK3 as a new therapeutic target in breast cancer. Nat Med 2011; 17: 715 719 [PMID: 21602804 DOI: 10.1038/nm.2351]

59 Grisouard J, Medunjanin S, Hermani A, Shukla A, Mayer D.Glycogen synthase kinase 3 protects estrogen receptor alpha from proteasomal degradation and is required for full transcriptional activity of the receptor. Mol Endocrinol 2007; 21: 2427 2439[PMID: 17609434 DOI: 10.1210/me.2007 0129]

60 Medina M, Wandosell F. Deconstructing GSK 3: The Fine Regulation of Its Activity. Int J Alzheimers Dis 2011; 2011: 479249 [PMID:21629747 DOI: 10.4061/2011/479249]

61 Medunjanin S, Hermani A, De Servi B, Grisouard J, Rincke G, Mayer D. Glycogen synthase kinase 3 interacts with and phosphorylates estrogen receptor alpha and is involved in the regulation of receptor activity. J Biol Chem 2005; 280: 33006 33014 [PMID: 16076840 DOI: 10.1074/jbc.M506758200]

62 Dennis AP, Haq RU, Nawaz Z. Importance of the regulation of nuclear receptor degradation. Front Biosci 2001; 6: D954 D959[PMID: 11487464 DOI: 10.2741/Dennis]

63 He X, Zheng Z, Song T, Wei C, Ma H, Ma Q, Zhang Y, Xu Y, Shi W,Ye Q, Zhong H. c Abl regulates estrogen receptor alpha transcription activity through its stabilization by phosphorylation. Oncogene 2010;29: 2238 2251 [PMID: 20101225 DOI: 10.1038/onc.2009.513]

64 Caligiuri I, Toffoli G, Giordano A, Rizzolio F. pRb controls estrogen receptor alpha protein stability and activity. Oncotarget 2013; 4:875 883 [PMID: 23900261 DOI: 10.18632/oncotarget.1036]

65 Zhu J, Zhao C, Kharman Biz A, Zhuang T, Jonsson P, Liang N,Williams C, Lin CY, Qiao Y, Zendehdel K, Strömblad S, Treuter E,Dahlman Wright K. The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor α and modulates estrogen stimulated breast cancer cell proliferation. Oncogene 2014; 33: 4340 4351 [PMID:24441041 DOI: 10.1038/onc.2013.573]

66 Yang H, Yu N, Xu J, Ding X, Deng W, Wu G, Li X, Hou Y, Liu Z, Zhao Y, Xue M, Yu S, Wang B, Li X, Niu G, Wang H, Zhu J,Zhuang T. SMURF1 facilitates estrogen receptor ɑ signaling in breast cancer cells. J Exp Clin Cancer Res 2018; 37: 24 [PMID:29433542 DOI: 10.1186/s13046 018 0672 z]

67 Zhuang T, Yu S, Zhang L, Yang H, Li X, Hou Y, Liu Z, Shi Y,Wang W, Yu N, Li A, Li X, Li X, Niu G, Xu J, Hasni MS, Mu K, Wang H, Zhu J. SHARPIN stabilizes estrogen receptor α and promotes breast cancer cell proliferation. Oncotarget 2017; 8:77137 77151 [PMID: 29100376 DOI: 10.18632/oncotarget.20368]

68 Wang S, Luo H, Wang C, Sun H, Sun G, Sun N, Zeng K, Song H, Zou R, Zhou T, Cong R, Liu W, Yang L, Li D, Zhou X, Zhong X, Lin L, Jiao J, Yan G, Wang X, Min X, Cao L, Zhao Y. RNF8 identified as a co activator of estrogen receptor α promotes cell growth in breast cancer. Biochim Biophys Acta 2017; 1863:1615 1628 [PMID: 28216286 DOI: 10.1016/j.bbadis.2017.02.011]

69 Chai F, Liang Y, Bi J, Chen L, Zhang F, Cui Y, Jiang J. REGγ regulates ERα degradation via ubiquitin proteasome pathway in breast cancer. Biochem Biophys Res Commun 2015; 456: 534 540[PMID: 25490392 DOI: 10.1016/j.bbrc.2014.11.124]

70 Liu H, Qiu J, Li N, Chen T, Cao X. Human phosphatidylethanolamine binding protein 4 promotes transactivation of estrogen receptor alpha(ERalpha) in human cancer cells by inhibiting proteasome dependent ERalpha degradation via association with Src. J Biol Chem 2010; 285:21934 21942 [PMID: 20460377 DOI: 10.1074/jbc.M110.109876]

71 Kim SH, Kang HJ, Na H, Lee MO. Trichostatin A enhances acetylation as well as protein stability of ERalpha through induction of p300 protein. Breast Cancer Res 2010; 12: R22 [PMID: 20388208 DOI: 10.1186/bcr2562]

72 La Rosa P, Pesiri V, Leclercq G, Marino M, Acconcia F.Palmitoylation regulates 17β-estradiol-induced estrogen receptor-α degradation and transcriptional activity. Mol Endocrinol 2012; 26:762 774 [PMID: 22446104 DOI: 10.1210/me.2011 1208]

73 Murphy LC, Seekallu SV, Watson PH. Clinical significance of estrogen receptor phosphorylation. Endocr Relat Cancer 2011; 18:R1 14 [PMID: 21149515 DOI: 10.1677/ERC 10 0070]

74 Thomas C, Gustafsson JÅ. Estrogen receptor mutations and functional consequences for breast cancer. Trends Endocrinol Metab 2015; 26: 467 476 [PMID: 26183887 DOI: 10.1016/j.tem.2015.06.007]

75 Yeh WL, Shioda K, Coser KR, Rivizzigno D, McSweeney KR, Shioda T. Fulvestrant induced cell death and proteasomal degradation of estrogen receptor α protein in MCF 7 cells require the CSK c Src tyrosine kinase. PLoS One 2013; 8: e60889 [PMID:23593342 DOI: 10.1371/journal.pone.0060889]

76 De Savi C, Bradbury RH, Rabow AA, Norman RA, Buttar D,Currie GS, Weir H, Donald C, Andrews D, MacFaul P, Ballard P,Curwen J, Wilson Z, Richmond G, D’Cruz C, Powell S, Walker G, Hulse M, Tonge M. Abstract 3650: Discovery of the clinical candidate AZD9496: a potent and orally bioavailable selective estrogen receptor downregulator and antagonist. Cancer Research 2015; 75: 3650[DOI: 10.1158/1538 7445.AM2015 3650]

77 Lai A, Kahraman M, Govek S, Nagasawa J, Bonnefous C, Julien J, Douglas K, Sensintaffar J, Lu N, Lee KJ, Aparicio A, Kaufman J, Qian J, Shao G, Prudente R, Moon MJ, Joseph JD, Darimont B,Brigham D, Grillot K, Heyman R, Rix PJ, Hager JH, Smith ND.Identification of GDC 0810 (ARN 810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen Resistant Breast Cancer Xenografts.J Med Chem 2015; 58: 4888 4904 [PMID: 25879485 DOI:10.1021/acs.jmedchem.5b00054]

78 Wardell SE, Nelson ER, Chao CA, McDonnell DP. Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen resistant breast cancer: implications for treatment of advanced disease. Clin Cancer Res 2013; 19: 2420 2431 [PMID: 23536434 DOI: 10.1158/1078 0432.CCR 12 3771]

79 Garner F, Shomali M, Paquin D, Lyttle CR, Hattersley G.RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs 2015; 26: 948 956 [PMID:26164151 DOI: 10.1097/CAD.0000000000000271]

80 Kim JA, Kim MR, Kim O, Phuong NT, Yun J, Oh WK, Bae K,Kang KW. Amurensin G inhibits angiogenesis and tumor growth of tamoxifen resistant breast cancer via Pin1 inhibition. Food Chem Toxicol 2012; 50: 3625 3634 [PMID: 22842120 DOI: 10.1016/j.fct.2012.07.027]

81 Kim JH, Jung JH, Kim SH, Jeong SJ. Decursin exerts anti cancer activity in MDA MB 231 breast cancer cells via inhibition of the Pin1 activity and enhancement of the Pin1/p53 association.Phytother Res 2014; 28: 238 244 [PMID: 23580332 DOI: 10.1002/ptr.4986]

82 Kotiyal S, Bhattacharya S. Breast cancer stem cells, EMT and therapeutic targets. Biochem Biophys Res Commun 2014; 453:112 116 [PMID: 25261721 DOI: 10.1016/j.bbrc.2014.09.069]

83 Li X, Li L, Zhou Q, Zhang N, Zhang S, Zhao R, Liu D, Jing Y,Zhao L. Synthesis of the novel elemonic acid derivatives as Pin1 inhibitors. Bioorg Med Chem Lett 2014; 24: 5612 5615 [PMID:25466185 DOI: 10.1016/j.bmcl.2014.10.087]

84 Moore JD, Potter A. Pin1 inhibitors: Pitfalls, progress and cellular pharmacology. Bioorg Med Chem Lett 2013; 23: 4283 4291 [PMID:23796453 DOI: 10.1016/j.bmcl.2013.05.088]

85 Potter A, Oldfield V, Nunns C, Fromont C, Ray S, Northfield CJ, Bryant CJ, Scrace SF, Robinson D, Matossova N, Baker L,Dokurno P, Surgenor AE, Davis B, Richardson CM, Murray JB, Moore JD. Discovery of cell active phenyl imidazole Pin1 inhibitors by structure guided fragment evolution. Bioorg Med Chem Lett 2010; 20: 6483 6488 [PMID: 20932746 DOI: 10.1016/j.bmcl.2010.09.063]

86 Wei S, Kozono S, Kats L, Nechama M, Li W, Guarnerio J, Luo M,You MH, Yao Y, Kondo A, Hu H, Bozkurt G, Moerke NJ, Cao S,Reschke M, Chen CH, Rego EM, Lo Coco F, Cantley LC, Lee TH,Wu H, Zhang Y, Pandol fi PP, Zhou XZ, Lu KP. Active Pin1 is a key target of all trans retinoic acid in acute promyelocytic leukemia and breast cancer. Nat Med 2015; 21: 457 466 [PMID: 25849135 DOI: 10.1038/nm.3839]

87 Xu GG, Slebodnick C, Etzkorn FA. Cyclohexyl ketone inhibitors of Pin1 dock in a trans diaxial cyclohexane conformation. PLoS One 2012; 7: e44226 [PMID: 23028504 DOI: 10.1371/journal.pone.0044226]

88 Stebbing J, Filipovic A, Ellis IO, Green AR, D’Silva TR, Lenz HJ, Coombes RC, Wang T, Lee SC, Giamas G. LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. Breast Cancer Res Treat 2012; 132: 537 544 [PMID:21671015 DOI: 10.1007/s10549 011 1622 z]

89 Stebbing J, Filipovic A, Lit LC, Blighe K, Grothey A, Xu Y, Miki Y,Chow LW, Coombes RC, Sasano H, Shaw JA, Giamas G. LMTK3 is implicated in endocrine resistance via multiple signaling pathways. Oncogene 2013; 32: 3371 3380 [PMID: 22869149 DOI:10.1038/onc.2012.343]

90 Zhao G, Guo J, Li D, Jia C, Yin W, Sun R, Lv Z, Cong X.MicroRNA 34a suppresses cell proliferation by targeting LMTK3 in human breast cancer mcf 7 cell line. DNA Cell Biol 2013; 32:699 707 [PMID: 24050776 DOI: 10.1089/dna.2013.2130]

91 Jacobs KM, Bhave SR, Ferraro DJ, Jaboin JJ, Hallahan DE,Thotala D. GSK 3β: A Bifunctional Role in Cell Death Pathways.Int J Cell Biol 2012; 2012: 930710 [PMID: 22675363 DOI:10.1155/2012/930710]

92 Kim HM, Kim CS, Lee JH, Jang SJ, Hwang JJ, Ro S, Choi J.CG0009, a novel glycogen synthase kinase 3 inhibitor, induces cell death through cyclin D1 depletion in breast cancer cells. PLoS One 2013; 8: e60383 [PMID: 23565238 DOI: 10.1371/journal.pone.0060383]

93 McCubrey JA, Davis NM, Abrams SL, Montalto G, Cervello M,Basecke J, Libra M, Nicoletti F, Cocco L, Martelli AM, Steelman LS. Diverse roles of GSK 3: tumor promoter tumor suppressor,target in cancer therapy. Adv Biol Regul 2014; 54: 176 196 [PMID:24169510 DOI: 10.1016/j.jbior.2013.09.013]

94 Mishra R. Glycogen synthase kinase 3 beta: can it be a target for oral cancer. Mol Cancer 2010; 9: 144 [PMID: 20537194 DOI:10.1186/1476 4598 9 144]

95 Ertel A, Dean JL, Rui H, Liu C, Witkiewicz AK, Knudsen KE,Knudsen ES. RB pathway disruption in breast cancer: differential association with disease subtypes, disease-speci fi c prognosis and therapeutic response. Cell Cycle 2010; 9: 4153 4163 [PMID:20948315 DOI: 10.4161/cc.9.20.13454]

96 Lehn S, Fernö M, Jirström K, Rydén L, Landberg G. A non functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen. Cell Cycle 2011; 10: 956 962 [PMID: 21358261 DOI: 10.4161/cc.10.6.15074]

97 Treré D, Brighenti E, Donati G, Ceccarelli C, Santini D, Taffurelli M, Montanaro L, Derenzini M. High prevalence of retinoblastoma protein loss in triple negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy.Ann Oncol 2009; 20: 1818 1823 [PMID: 19556322 DOI: 10.1093/annonc/mdp209]

98 Witkiewicz AK, Knudsen ES. Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions. Breast Cancer Res 2014; 16: 207 [PMID:25223380 DOI: 10.1186/bcr3652]

99 Alam M, Rajabi H, Ahmad R, Jin C, Kufe D. Targeting the MUC1 C oncoprotein inhibits self renewal capacity of breast cancer cells.Oncotarget 2014; 5: 2622 2634 [PMID: 24770886 DOI: 10.18632/oncotarget.1848]

100 Kharbanda A, Rajabi H, Jin C, Raina D, Kufe D. Oncogenic MUC1 C promotes tamoxifen resistance in human breast cancer.Mol Cancer Res 2013; 11: 714 723 [PMID: 23538857 DOI:10.1158/1541 7786.MCR 12 0668]

101 Pitroda SP, Khodarev NN, Beckett MA, Kufe DW, Weichselbaum RR. MUC1 induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment.Proc Natl Acad Sci USA 2009; 106: 5837 5841 [PMID: 19289846 DOI: 10.1073/pnas.0812029106]

102 Alam M, Bouillez A, Tagde A, Ahmad R, Rajabi H, Maeda T,Hiraki M, Suzuki Y, Kufe D. MUC1 C Represses the Crumbs Complex Polarity Factor CRB3 and Downregulates the Hippo Pathway. Mol Cancer Res 2016; 14: 1266 1276 [PMID: 27658423 DOI: 10.1158/1541 7786.MCR 16 0233]

103 Jin C, Rajabi H, Kufe D. miR 1226 targets expression of the mucin 1 oncoprotein and induces cell death. Int J Oncol 2010; 37:61 69 [PMID: 20514397]

104 Sachdeva M, Mo YY. MicroRNA 145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 2010; 70:378 387 [PMID: 19996288 DOI: 10.1158/0008 5472.CAN 09 2021]

105 Lacunza E, Baudis M, Colussi AG, Segal Eiras A, Croce MV,Abba MC. MUC1 oncogene ampli fi cation correlates with protein overexpression in invasive breast carcinoma cells. Cancer Genet Cytogenet 2010; 201: 102 110 [PMID: 20682394 DOI: 10.1016/j.cancergencyto.2010.05.015]

106 Rajabi H, Jin C, Ahmad R, McClary C, Joshi MD, Kufe D.MUCIN 1 ONCOPROTEIN EXPRESSION IS SUPPRESSED BY THE miR 125b ONCOMIR. Genes Cancer 2010; 1: 62 68 [PMID:20729973 DOI: 10.1177/1947601909357933]

107 Zhou Y, Rajabi H, Kufe D. Mucin 1 C terminal subunit oncoprotein is a target for small molecule inhibitors. Mol Pharmacol 2011; 79:886 893 [PMID: 21346142 DOI: 10.1124/mol.110.070797]

108 Yuan S, Shi C, Ling R, Wang T, Wang H, Han W. Immunization with two recombinant Bacillus Calmette Guérin vaccines that combine the expression of multiple tandem repeats of mucin 1 and colony stimulating factor suppress breast tumor growth in mice. J Cancer Res Clin Oncol 2010; 136: 1359 1367 [PMID: 20127358 DOI: 10.1007/s00432 010 0787 x]

109 Yuan S, Shi C, Liu L, Han W. MUC1 based recombinant Bacillus Calmette Guerin vaccines as candidates for breast cancer immuno therapy. Expert Opin Biol Ther 2010; 10: 1037 1048 [PMID: 20420512 DOI: 10.1517/14712598.2010.485185]

110 Kotzsch M, Kirchner T, Soelch S, Schäfer S, Friedrich K, Baretton G, Magdolen V, Luther T. Inverse association of rab31 and mucin 1(CA15 3) antigen levels in estrogen receptor positive (ER+)breast cancer tissues with clinicopathological parameters and patients’ prognosis. Am J Cancer Res 2017; 7: 1959 1970 [PMID:28979817]

111 Fowler AM, Solodin N, Preisler Mashek MT, Zhang P, Lee AV,Alarid ET. Increases in estrogen receptor alpha concentration in breast cancer cells promote serine 118/104/106 independent AF 1 transactivation and growth in the absence of estrogen. FASEB J 2004; 18: 81 93 [PMID: 14718389 DOI: 10.1096/fj.03 0038com]

112 Fowler AM, Solodin NM, Valley CC, Alarid ET. Altered target gene regulation controlled by estrogen receptor alpha concentration.Mol Endocrinol 2006; 20: 291 301 [PMID: 16179380 DOI:10.1210/me.2005 0288]